Acrivon reports new mouse-model data showing complete tumor regression and immune memory for ACR-368 and ACR-2316 combos

Acrivon Therapeutics, Inc.

Syngeneic mouse model: sustained complete tumor regression and immune memory after multiple implant rounds over ~1 year.
Data supports rationale for front-line combination of ACR-368 and ACR-2316 with anti-PD(L)1 agents.
Pipeline update adds all-comer ACR-368 + ULDG ARM 3 of ongoing ACR-368-201 trial.
AP3 platform update highlights capability to generate actionable pathway insights for novel drug design.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.